Advertisement
Case Report| Volume 35, ISSUE 3, P404-406, June 2022

Download started.

Ok

Aggressive Intra-Abdominal Fibromatosis in an Adolescent Girl – An Unusual Sequelae to Ovarian Germ Cell Tumor

Published:December 23, 2021DOI:https://doi.org/10.1016/j.jpag.2021.12.011

      Background

      Abdominal fibromatosis presenting as an abdominal mass is a rare occurrence in a gynecological setting. The diagnosis might not be suspected preoperatively, and management could be challenging.

      Case

      An 18-year-old girl with ovarian germ cell malignancy was managed with staging laparotomy and chemotherapy. She developed a large abdominal mass 10 months later. An abdominopelvic mass (40 × 20 cm) was removed at laparotomy. The histopathological diagnosis was intra-abdominal fibromatosis. A rapidly growing abdominal mass recurred postoperatively. After discussion with the tumor board, chemotherapy with methotrexate and vinblastine was started. The tumor was not responsive, and the patient succumbed after the second cycle of chemotherapy.

      Summary and Conclusion

      Abdominal fibromatosis should be considered among the differential diagnoses of a rapidly growing abdominal mass after resection of an ovarian germ cell tumor.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Fletcher CDM, Bridge JA, Hogendoorn P, et al: WHO Classification of Tumours of Soft Tissue and Bone (IARC WHO Classification of Tumours), 4th ed. 2013.

        • Penel N
        • Coindre JM
        • Bonvalot S
        • et al.
        Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France.
        Eur J Cancer. 2016; 58: 90-96
        • Sanchez-Mete L
        • Ferraresi V
        • Caterino M
        • et al.
        Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series.
        J Clin Med. 2020; 9: 4012
        • Wu C
        • Amini-Nik S
        • Nadesan P
        • et al.
        Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells.
        Cancer Res. 2010; 70: 7690-7698
        • Miyoshi Y
        • Iwao K
        • Nawa G
        • et al.
        Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis.
        Oncol Res. 1998; 10: 591-594
        • Navin P
        • Lehrke HD
        • Schmitz JJ
        • et al.
        Desmoid fibromatosis mimicking metastatic recurrence after pancreatectomy for pancreatic adenocarcinoma.
        Mayo Clin Proc Innov Qual Outcomes. 2018; 2: 392-397
        • Alman B
        • Attia S
        • Baumgarten C
        • et al.
        The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients.
        Eur J Cancer. 2020; 127: 96-107
        • Azzarelli A
        • Gronchi A
        • Bertulli R
        • et al.
        Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.
        Cancer. 2001; 92: 1259-1264